Drug Trial Radar · NCT00276094
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
Last checked: Nov 20, 2026Latest source record: Jun 28, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
826
Actual
Start
Jan 2006
Primary completion
Not stated
Study completion Dec 2007
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- Collaborators
- Hormos Medical; QuatRx Pharmaceuticals
- First posted
- Jan 12, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
Conditions
- Atrophy
- Vaginal Diseases
Interventions
Ospemifene 30 mgDrug
1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
Ospemifene 60 mgDrug
1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
PlaceboDrug
1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
Nonhormonal vaginal lubricantDrug
Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom (MBS) of Vaginal DrynessTime frame: Baseline (Randomization) to Week 12
- Mean Change From Baseline in the MBS of Vaginal Pain Associated With Sexual ActivityTime frame: Baseline (Randomization) to Week 12
- Mean Change From Baseline in Vaginal pHTime frame: Baseline (Screening) to Week 12
- Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal SmearTime frame: Baseline (Screening) to Week 12
- Mean Change From Baseline in the Percentage of Superficial Cells in Maturation Index of Vaginal SmearTime frame: Baseline (Screening) to Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.